author-photo

Jeffrey R. Jackson

GlaxoSmithKline

38

Papers

2021

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.

2010 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (32)
Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.

2010 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (16)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.

2010 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (266)
Corrigendum to “Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding” [Bioorg. Med. Chem. Lett. 19 (2009) 1694]

2009 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (4)
Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

2009 Cancer Research
Show All
- Source
- Cite
- Save
Citations (100)
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

2009 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (49)
Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3‐kinase and the mammalian target of rapamycin (mTOR)

2009 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
567 POSTER GSK1120212 is a novel Mek inhibitor demonstrating sustained inhibition of ERK phosphorylation and selective inhibition of B-Raf and RAS mutant cells in preclinical models

2008 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (2)
Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint.

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (40)
In vitro sensitivity data suggests targeting several tumor types and molecular subtypes with the PI3K inhibitor GSK1059615 could maximize response rates in early clinical trials

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)